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Abstract: Roots of Plumbago zeylanica have been reported to improve 
learning and memory of mice, but the effect of plumbagin on learning and 
memory of mice and the possible mechanisms for its effect on memory have 
not been explored till date. So the present study was designed to evaluate the 
effect of plumbagin on learning and memory of Swiss young male albino 
mice. Plumbagin (4, 8, 16 mg/kg, p.o.) and physostigmine (0.1 mg/kg,i.p.) 
per se were administered for 15 successive days to separate groups of 
mice. Behavioral parameters of learning and memory were recorded using 
Morris water maze. Acetylcholinesterase activity was estimated in brain of 
mice. Effect of plumbagin on scopolamine (0.4 mg/kg, i.p.) and diazepam 
(1 mg/kg, i.p.)-induced amnesia was also investigated. Locomotor activities 
of mice were also recorded. Plumbagin (8 and 16 mg/kg) and physostigmine 
significantly improved learning and memory of mice, as indicated by decrease 
in escape latency during training and increase in time spent in target quadrant 
of Morris water maze during retrieval. The drugs did not show any significant 
effect on locomotor activities of mice. Memory improving activity of plumbagin 
(16 mg/kg) was equivalent to physostigmine. Plumbagin significantly reversed 
scopolamine- and diazepam- induced amnesia in mice. Plumbagin and 
physostigmine also significantly reduced brain acetylcholinesterase activity 
of mice. In conclusion, plumbagin significantly improved memory of mice 
possibly through inhibition of brain acetylcholinesterase activity and through 
involvement of GABA-benzodiazepine pathway. Thus, plumbagin may be 
explored further for management of cognitive dysfunction. 






Learning is acquisition of new knowledge and skills, whereas memory is 
retention and retrievals of facts composed of experiences (Kumar et al., 
2012). Alzheimer’s disease is a progressive neurodegenerative disorder 
characterized by the gradual onset of dementia. It is characterized by 
gradually progressive decline in cognitive function, with deficits especially 
in memory retrieval (Kalaria et al., 2008). The primary cause of Alzheimer’s 
disease appears to be reduction in cholinergic activity. Acetylcholinesterase 
enzyme (AChE) plays a key role in the regulation of the cholinergic system 
and hence, inhibition of AChE is a most promising target for the treatment of 
Alzheimer’s disease (Lu et al., 2010). A number of cholinesterase inhibitors 
like donepezil, rivastigmine, tacrine and rivastigmine etc. are in practice 
for the treatment of various cognitive disorders (Ellis, 2005). However, 
the adverse effects associated with anti-cholinesterase drugs (rivastigmine, 
galantamine, donepezil) include anorexia, nausea, vomiting, diarrhoea, and 
insomnia (Kavirajan and Schneider, 2007). Physostigmine, a cholinesterase 
inhibitor, improved memory of Alzheimer’s disease patients (Mohs et al., 
1985). But this drug has a short half-life and requires complex forms of 
administration (Filho and Birks, 2001). So there is a need to discover new 
drugs with better efficacy and having less adverse effects. Plants have been 
used since ancient times in traditional medicinal systems for the treatment 
of memory dysfunction. Bacopa monniera, commonly called as Brahmi, 
has been proven to be clinically effective in treatment of cognitive disorders 
(Pase et al., 2012). The bioactive compounds isolated from plants such as 
galantamine (Raskind et al., 2000), huperzine alpha (Zhang et al., 2002), 
etc.  have been reported to be effective for treatment of cognitive deficits in 
patients of dementia.
Plumbagin, an active constituent of Plumbago zeylanica roots, has been 
reported to possess various pharmacological activities such as antioxidant 
(Kumar et al., 2013), neuroprotective (Son et al., 2010), antiparkinsonian 
(Choi et al., 2012), anti-inflammatory (Lou et al., 2010) and antidepressant 
(Dhingra and Bansal, 2015). Plumbago zeylanica roots have been reported 
to improve learning and memory of mice (Mittal et al., 2010), but the effect 
of plumbagin on learning and memory of mice has not been explored till 
date. Therefore, the present study was designed to investigate the effect of 
plumbagin on learning and memory of mice by employing behavioral models.
2. MATERIALS AND METHODS
2.1 Experimental animals
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Swiss male albino mice, weighing around 25-30 g, were purchased from 
Disease Free Small Animal House, Lala Lajpat Rai University of Veterinary 
and Animal Sciences, Hisar (Haryana, India). Female mice were not included 
in the study because estrogens (female sex hormones) have been found to have 
memory improving effect (Harburger et al., 2007), so we excluded female 
mice and used only male mice. Animals were housed separately in groups of 
6 - 7 per cage (Polycarbonate cage size: 29×22×14 cm) under proper laboratory 
conditions with alternating light and dark cycle of 12 h each. The animals had 
free access to food and water, except food was withdrawn 2 h before and 2 
h after drug administration. The animals were acclimatized for at least five 
days before behavioral experiments which were carried out between 09:00 
and 17:00 h. The experimental protocol was approved by Institutional Animals 
Ethics Committee (IAEC) and animal care was taken as per the guidelines 
of Committee for the Purpose of Control and Supervision of Experiments on 
Animals (CPCSEA), Ministry of Environment and Forests, Government of 
India.
2.2 Drugs and chemicals
Plumbagin (Sigma-Aldrich, St. Louis, USA); physostigmine (Hi-Media 
Laboratories, Mumbai); Carboxy methyl cellulose (CDH- Central Drug 
House, New Delhi); Scopolamine hydrobromide (Sigma-Aldrich, St. Louis, 
USA);Acetylcholine iodide; 5, 5’-dithiobis-2- nitrobenzoic acid (Hi-Media 
laboratories Pvt. Ltd., Mumbai); Acetyl thiocholine iodide (Hi-Media 
laboratories Pvt. Ltd., Mumbai) were used in the present study.
2.3 Selection of doses
Doses of various drugs were selected on the basis of literature, i.e. 4, 8 and 
16 mg/kg for plumbagin (Sivakumar et al., 2005), 0.4 mg/kg for scopolamine 
(Dhingra et al., 2004), 0.1 mg/kg for physostigmine (Sharma and Kulkarni, 
1992).
2.4 Vehicle
Plumbagin was dissolved in 1% w/v carboxy methyl cellulose (CMC) solution. 
Scopolamine hydrobromide was dissolved in normal saline. 
2.5 Laboratory model employed for evaluation of effect of plumbagin on 
learning and memory of mice




The procedure and parameters for testing learning and memory of mice 
using Morris water maze were followed as reported earlier (Domange 
et al., 2013; Morris, 1984; Park and Singh, 2007). Briefly, Morris 
water maze for mice consisted of a circular pool (60 cm in diameter, 
25 cm in height) filled to a depth of 20 cm with water maintained at 
25° C. The water was made opaque with non-toxic white colored dye (Pidilite 
Ltd., Maharashtra, India). Two threads were fixed at right angle to each 
other on rim of the pool to divide the tank into four equal quadrants. Four 
quadrants were designated as Q1, Q2, Q3 and Q4. A submerged platform 
(with top surface 6 cm × 6 cm and painted in white) was placed inside the 
target quadrants (Q4 in present study) of this pool 1 cm below surface of 
water. The position of platform was kept at the same place throughout the 
training session. Each animal was subjected to four consecutive trials each 
day with a gap of 5 min for four consecutive days (starting from 11th day of 
drug administration to 14th day), during which they were allowed to escape 
on to the hidden platform and to remain there for 20 sec. During the training 
session, the mouse was gently placed in one of the quadrants, facing the wall 
of pool with drop location changing for each trial, and allowed 120 sec to 
locate submerged platform. If the mouse failed to find the platform within 
120 s, it was guided gently on to the platform and allowed to remain there 
for 20 s. Escape latency (EL) is the time taken by the animal to move from 
the starting quadrant to find the hidden platform in the target quadrant. From 
11th day to 14th day of training session, EL was recorded for each animal. 
Each animal was subjected to training trials for four consecutive days, the 
starting position was changed with each exposure as mentioned below and 
target quadrant (Q4 in the present study) remained constant throughout the 
training period. 
Day 1 Q 1 Q 2 Q 3 Q 4
Day 2 Q 2 Q 3 Q 4 Q 1
Day 3 Q 3 Q 4 Q 1 Q 2
Day 4 Q 4 Q 1 Q 2 Q 3
On the fifth day (i.e. 15th day of drug administration), platform was 
removed and mouse was placed in any of the three quadrants except Q4 and 
allowed to explore the target quadrant for 300 sec. The mean time spent in 
the target quadrant in search of the missing platform was noted as index of 
retrieval or memory. The observer always stood at the same position. Care was 
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taken not to disturb the relative location of water maze with respect to other 
objects in the laboratory. 
2.5.2 Measurement of locomotor activity
Locomotor activities of control and drug-treated animals were measured for a 
period of 5 min using photoactometer (INCO, Ambala, India) (Dhingra et al., 
2012).
2.6 Biochemical estimation
2.6.1 Collection of brain sample
After recordings behavioral parameters on 15th day using Morris water maze, 
the animals were sacrificed on 16th day by cervical dislocation. Whole brain 
was carefully removed from the animals. For preparation of brain homogenate, 
the fresh whole brain was weighed first and then homogenized in 10 volumes 
of 0.1 M phosphate buffer (pH 8) using a glass homogenizer. The homogenate 
was centrifuged at 3000 rpm for 10 min at 4°C using refrigerated centrifuge 
(Remi, Mumbai). The resultant cloudy supernatant liquid was used for the 
estimation of brain acetyl cholinesterase activity.
2.6.2 Estimation of brain acetylcholinesterase activity
Brain acetyl cholinesterase activity was estimated by the method as reported 
earlier (Ellman et al., 1961). 0.4 ml of brain homogenate was added into a test 
tube containing 2.6 ml of phosphate buffer. 5,5-dithiobis-2-nitrobenzoic acid 
reagent (0.1 ml) was added to the above mixture and absorbance was noted at 
412 nm. Then 0.02 ml of acetylcholine iodide solution was added and again 
absorbance was noted 15 min thereafter. Change in absorbance per minute was 
calculated. The following formula was used to calculate rate of hydrolysis of 
substrate:
R= Change in absorbance/min × 5.74 × 10-4/ C0
R= Rate of hydrolysis of acetylcholine iodide/ min/ mg tissue
C0= weight of tissue homogenate in mg/ml.
2.7. Experimental protocol
2.7.1 Groups for Morris water maze
Groups 1 to 5 (n = 7 each): CMC(1%w/v), plumbagin (4, 8 and 16 mg/kg, 
p.o.) and physostigmine (0.1 mg/kg i.p.), respectively were administered for 




administration from 11th day to 14th day. On 15th day, time spent in target 
quadrant (TSTQ) was noted 120 min after the drug administration. In case of 
animals administered with physostigmine, EL and TSTQ was noted after 30 
min of drug administration.
Groups 6 and 7 (n = 6 each): CMC (1% w/v) and plumbagin (16mg/kg, 
p.o.) respectively were administered for 15 successive days. EL was recorded 
120 min after drug administration from 11th day to 14th day.  On 15th day, 
scopolamine (0.4 mg/kg) was injected 30 min after oral administration 
of plumbagin (16mg/kg) and TSTQ was noted 45 min after injection of 
scopolamine.
Groups 8 and 9 (n = 7 each): CMC (1% w/v) and plumbagin (16mg/kg, 
p.o.) respectively were administered for 15 successive days. EL was recorded 
120 min after drug administration from 11th day to 14th day.  On 15th day, 
diazepam (1 mg/kg, i.p.) was injected 30 min after oral administration of 
plumbagin (16 mg/kg) and TSTQ was noted 45 min after injection of diazepam.
2.7.2 Groups for locomotor activity
Groups 10 to14 (n=6 each group): CMC (1%w/v), plumbagin (4, 8 and 16 mg/
kg,p.o.) and physostigmine (0.1 mg/kg,i.p.), respectively were administered 
for 15 successive days. Locomotor activity was measured on 15th day using 
actophotometer (INCO, Ambala).
2.7.3 Groups for biochemical estimation
Brain acetylcholinesterase activity was measured 24 hour after behavior testing 
on animals of groups 1 to 5.
2.8 STATISTICAL ANALYSIS
All the results are expressed as Mean ± S.E.M. Data were analyzed by analysis 
of variance (ANOVA) followed by Tukey’s post hoc test in Graph Pad Instat 
version 3.05. p< 0.05 was considered as significant
3. RESULTS
3.1 Effect of plumbagin and other drugs employed on escape latency (EL) 
and time spent in target quadrant (TSTQ) of mice using Morris water maze
Decrease of EL and increase of TSTQ by mice in Morris water maze indicates 
improvement of learning and memory and vice versa.  Physostigmine (0.1mg/
kg, i.p.) and highest dose (16 mg/kg, p.o.) of plumbagin per se administered for 
15 successive days significantly decreased EL of mice from 11th to 14th day and 
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Table 1: Effect of plumbagin and physostigmine on escape latency (EL) of mice 

















Control (vehicle) 10ml 95.32 ± 1.35 94.00 ± 1.53 92.68 ± 1.36 90.62 ± 5.45
Physostigmine 0.1mg 51.96 ± 5.58a 48.67 ± 1.42a 55.39 ±1 .82a 42.07 ± 1.45a
Plumbagin 4 mg 94.53 ±1.81ns 89.07 ± 2.37ns 78.96 ± 1.88a 68.75 ± 1.44a
Plumbagin 8 mg 85.82 ± 1.00ns 81.00 ± 0.512ns 53.39 ± 1.51a 42.14 ± 1.46a
Plumbagin 16 mg 51.94 ± 2.13a 57.90 ± 1.99a 57.87 ± 2.04a 57.31 ± 1.31a
n=7 each group. Values are expressed as Mean ± SEM. Data was analyzed by one-way 
ANOVAfollowed by Tukey’s Post-hoc test.
F (4, 30) = 58.946; p<0.0001 (Day 11)
F (4, 30) = 125.53; p<0.0001 (Day 12)
F (4, 30) = 99.395; p<0.0001 (Day 13)
F (4, 30) = 55.057; p<0.0001 (Day 14)
a = p< 0.001; as compared to control group; ns =non-significant
Table 2: Effect of plumbagin and other drugs employed on time spent in target 
quadrant (TSTQ) of Morris Water Maze.




Time spent (sec) in target 
quadrant (15th day)
Control (vehicle) 7 10  ml 38.42 ± 2.88
Physostigmine 7 0.1 mg 158.71±3.35b
Plumbagin 7 4 mg 41.14±4.06ns
Plumbagin 7 8 mg 47.00 ± 4.32a
Plumbagin 7 16 mg 127.00±4.80b
Scopolamine 6 0.4 mg 28.14±5.18b
Diazepam 7 1 mg 29.57±3.26a
Plumbagin+ scopolamine 6 16 mg+0.4 mg 71.85 ± 2.91c
Plumbagin+ diazepam 7 16 mg + 1 mg 65.14±2.61d
Values are expressed as Mean ± SEM. Data was analyzed by one-way ANOVA followed by 
Tukey’s Post-hoc test.
F (8, 54) = 1016.7; p<0.0001
a= p<0.01; b = p<0.001 as compared to control; c = p<0.001 as compared to scopolamine; d = 




increased TSTQ by mice on 15th day as compared to the control, thus showed 
significant improvement of learning and memory. The lowest dose (4 mg/kg, 
p.o.) and middle dose (8 mg/kg, p.o.) of plumbagin significantly decreased EL 
on 13th and 14th days; and did not significantly affect EL on 11th and 12thdays. 
Middle dose (8 mg/kg, p.o.) of plumbagin also significantly increased TSTQ as 
compared to vehicle treated control. Scopolamine (0.4 mg/kg i.p.) and diazepam 
(1 mg/kg, i.p.) per se administered on 15th day significantly decreased TSTQ by 
mice, indicating their amnesic effects. Plumbagin (16 mg/kg, p.o.) significantly 
reversed scopolamine-and diazepam-induced amnesia as compared to respective 
scopolamine and diazepam treated groups (Tables 1 and 2). 
3.2 Effect of plumbagin and physostigmine on brain AChE activity of mice
Table 3: Effect of plumbagin and physostigmine on brain AChE activity of mice.
Treatment for 15 days Dose (kg)-1 Acetylcholinesterase activity
(mol/l per min × 10-6/g of tissue)
Control (1% w/v CMC) 10 ml 0.057 ± 0.005
Physostigmine 0.1 mg 0.0185 ± 0.002a
Plumbagin 4 mg 0.043 ± 0.005a
Plumbagin 8 mg 0.025 ± 0.001a
Plumbagin 16 mg 0.022 ± 0.003a
n=6 each group. Values are expressed as Mean ± SEM. Data was analyzed by one-way 
ANOVA followed by Tukey’s Post-hoc test.
F (4, 25) =21.211; p<0.0001
a= p<0.01 as compared to control;
Table 4: Effect of plumbagin and physostigmine on locomotor activity of mice.
Treatment Dose (kg-1) Locomotor activity counts / 5 min
Control 10ml 430.5 ± 8.59
Physostigmine 0.1mg 415.83 ± 10.29
Plumbagin 4 mg 429 ± 9.67
Plumbagin 8 mg 442 ± 20.67
Plumbagin 16 mg 418 ± 1 2.50
n= 6 each group. Values are expressed as Mean ± SEM. Data was analyzed by one-way 
ANOVA followed by Tukey’s Post-hoc test.
F (4, 25) =0.6522; p=0.6307 
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Administration of plumbagin (8 and 16 mg/kg) and physostigmine per se for 
15 consecutive days produced a significant decrease in brain AChE activity as 
compared to control group. The lowest dose of plumbagin (4 mg/kg) did not 
produce significantly decrease in AChE activity as compared to control group 
(Table 3).
3.3 Effect of plumbagin and physostigmine on locomotor activity of mice.
Plumbagin (4, 8 and 16 mg/kg) and physostigmine per se administered for 
15 consecutive days did not significant affect locomotor activity of mice as 
compared to vehicle treated control (Table 4).
4. DISCUSSION
In the present study, plumbagin (16mg/kg) administered for 15 successive 
days significantly improved learning and memory of mice. Memory 
improving effect of plumbagin was comparable to physostigmine, a well 
known anticholinesterase nootropic drug. Morris water maze was employed 
as a behavioral model for evaluation of learning and memory. Plumbagin 
significantly decreased EL during training and it significantly increased TSTQ 
during retrieval, indicating improvement of learning and memory. It did not 
show any significant change on locomotor activities of mice as compared 
to the vehicle treated control, so this compound did not produce any motor 
effects. Thus, memory enhancing effect of plumbagin is specific and not false 
positive. Out of the three doses (4, 8 and 16 mg/kg, p.o.) of plumbagin, highest 
dose (16 mg/kg) produced better (p<0.001) memory enhancing effect in mice 
as compared to middle dose of (8 mg/kg) (p <0.05), whereas lowest dose (4 
mg/kg) did not show significant memory improving effect. Hence, the highest 
dose (16 mg/kg) of plumbagin was employed for elucidating its probable 
mechanisms of memory improving activity.
In the present study, scopolamine and diazepam significantly impaired 
memory of mice. Memory impairment effect of scopolamine and diazepam has 
been reported in the literature (Parle & Dhingra, 2003). Plumbagin (16 mg/kg, 
p.o.) administered for 15 successive days significantly reversed scopolamine- 
and diazepam- induced amnesia in mice. Benzodiazepines produce 
amnesia in laboratory animals by activation of benzodiazepine receptors 
and GABAergic system (Singh et al., 1998). Flumazenil (benzodiazepine-
receptor antagonist) and beta-carbolines (benzodiazepine inverse agonist) 
have been reported to reverse benzodiazepine-induced amnesia (Jensen 
et al., 1987). Reversal of scopolamine- and diazepam-induced amnesia by 




inhibition of GABA-benzodiazepine pathway. Acetylcholine is considered as 
the most important neurotransmitter involved in the regulation of cognitive 
functions (Hasselmo, 2006). Selective loss of cholinergic neurons and / or 
decreased synthesis of acetylcholine were reported to be a characteristic 
feature of dementia of Alzheimer’s disease type (Watanabe et al., 2009). 
Drugs that reduce cholinergic function such as muscarinic receptor antagonist, 
scopolamine cause profound memory impairments in animals and humans 
(Deutsch and Rocklin, 1967).  In the present study, scopolamine significantly 
impaired memory of mice. Plumbagin (16 mg/kg, p.o.) administered for 
15 successive days significantly reversed scopolamine-induced amnesia in 
mice. Reversal of scopolamine-induced amnesia by plumbagin indicated 
the possible facilitation of cholinergic transmission.  Plumbagin (16 mg/
kg) also significantly reduced brain AChE activity in mice as compared to 
the control. This suggests that the memory enhancing effect of plumbagin 
might be due to inhibition of AChE, leading to increase in brain acetylcholine 
levels. Acetylcholine is considered to be the most important neurotransmitter 
involved in the regulation of cognitive functions. Cognitive dysfunction has 
been shown to be associated with impaired cholinergic transmission and 
the facilitation of central cholinergic transmission resulting in improved 
memory. The degeneration and dysfunction of cortical cholinergic neurons 
is closely associated with cognitive deficits of Alzheimer’s disease (Bartus et 
al., 1982; Coyle et al., 1983; Watanabe et al., 2009). Thus, the drugs which 
enhance cholinergic function can be used for treatment of dementia closely 
related to Alzheimer’s disease. Physostigmine (0.1 mg/kg, i.p.) injected for 
15 successive days significantly improved memory of mice.The memory 
enhancing effect of physostigmine is in line with the earlier studies (Bekker 
et al., 2007). The memory improving effect of plumbagin was comparable to 
physostigmine. 
5. CONCLUSION
Plumbagin administered for 15 successive days significantly improved learning 
and memory of mice probably through inhibition of brain acetylcholinesterase 
activity and through involvement of GABA-benzodiazepine pathway. Further 
studies may be carried out to explore the other possible mechanisms for 
nootropic activity of plumbagin and its usefulness in the management of 
cognitive disorders.
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